FDA Adds Vision-Loss Warning to GLP-1 Diabetes Drugs
Adults taking GLP-1 receptor agonists now face a labeled warning about a rare condition that can cause sudden vision loss.
Updated on Nov. 9, 2026 in Diabetes

The FDA is requiring manufacturers of all GLP-1 receptor agonist drugs, including semaglutide and tirzepatide-class medicines used for type 2 diabetes and weight management, to add warnings about the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden vision loss. The action follows a review that found a higher NAION incidence in patients taking these drugs than in comparison groups.
Why it matters
For adults with diabetes who take a GLP-1 drug, the change means vision loss is now formally listed among the labeled risks, which may shape how prescribers counsel patients about symptoms to report. The review was prompted by a July 2024 article on semaglutide and NAION, and the FDA's added warning reflects its assessment of that signal across the drug class.
The FDA pooled 126 GLP-1 receptor agonist trials involving 134,253 patients, identifying 15 probable NAION events, while a Sentinel cohort study covering 2019 to 2024 compared risk against other diabetes drug classes. The NAION rate was 6.4 per 100,000 person-years on GLP-1 RAs versus 3.8 on comparator drugs, but the SGLT-2 comparison was not statistically significant.
The players
U.S. Food and Drug Administration (FDA)
The federal agency that regulates prescription drug safety and labeling in the United States, and which oversees the monitoring of adverse events for GLP-1 receptor agonists.
Hathaway et al.
Researchers whose July 2024 article on semaglutide and NAION risk prompted the FDA's further review of the signal.
The details
NAION occurs when blood flow to the optic nerve is interrupted, damaging the nerve and often causing sudden, painless vision loss in one eye. The FDA reviewed adverse event reports from its adverse event monitoring system and conducted a retrospective cohort study using the Sentinel real-world data network. Published observational studies have consistently reported higher NAION risk with GLP-1 RAs than with DPP-4 or SGLT-2 inhibitors, though the FDA's animal data review did not identify a specific mechanism.
Timeline
July 2024: Hathaway et al. published an article on semaglutide and NAION risk, prompting further FDA assessment.
2019 to 2024: Study period for the Sentinel cohort of adults with type 2 diabetes.
November 9, 2026: The FDA published the safety labeling change requirement.
Health Landscape
GLP-1 receptor agonists have become a central treatment for type 2 diabetes and are widely used for weight management, making their long-term safety profile a major population-level concern. This labeling change adds to a growing body of post-market safety review for the class as its use has expanded.
If you take a GLP-1 receptor agonist and notice sudden blurring or loss of vision in one eye, contact your doctor promptly rather than waiting. Worth raising with your prescriber at your next visit is whether the new labeling changes anything about your treatment plan.
The takeaway
The FDA's labeling change makes vision loss from NAION a formally listed risk across the entire GLP-1 drug class, and the evidence shows a higher rate than comparison diabetes medications, though the mechanism is not yet understood. Anyone with diabetes taking one of these drugs should discuss the new warning and any vision symptoms with their physician.
Further reading
For broader context on how these medications are managed, see Diabetes coverage in the United States.





